Streetbeat News

Stock Prices

BPTS

Biophytis SA's shares are surging after the company concluded an agreement with SEQENS to produce the active compound in Sarconeos (BIO101), its main drug candidate. The drug is being developed for severe forms of Covid-19, sarcopenia, and Duchenne muscular dystrophy. Biophytis recently filed for FDA approval to launch its SARA-31 program in the U.S., the first-ever Phase 3 study in sarcopenia.

Portfolio Pulse from Vandana Singh

July 18, 2023 | 1:19 pm

MS

Morgan Stanley reported Q2 earnings per share of $1.24, beating the consensus of $1.15. Revenues reached $13.46 billion, up 2% Y/Y, but down 7% sequentially. The bank's profit declined 13% to $2.18 billion due to a slowdown in deal-making and trading. Despite this, wealth management revenue rose 16% to $6.66 billion on higher interest income. The institutional securities business posted an 8% decline in revenue to $5.65 billion.

Portfolio Pulse from Vandana Singh

July 18, 2023 | 1:16 pm

WFC

Wells Fargo's short percent of float has decreased by 10.59% since its last report, with 28.50 million shares sold short, representing 0.76% of all regular shares available for trading. This decrease in short interest could indicate a more bullish market sentiment towards Wells Fargo. Compared to its peers, Wells Fargo has less short interest as a percentage of float, with an average of 0.97%.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:15 pm

DAL

Delta Air Lines's (NYSE:DAL) short percent of float has fallen 18.96% since its last report, with 20.43 million shares sold short, which is 3.59% of all regular shares available for trading. This decrease in short interest could signal a more bullish market sentiment towards Delta Air Lines. Compared to its peers, Delta has less short interest as a percentage of float, with an average of 7.06%.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:15 pm

DDOG

Datadog's (NYSE:DDOG) short percent of float has risen 13.07% since its last report, with 11.53 million shares sold short, which is 4.24% of all regular shares available for trading. This increase in short interest can act as an indicator of market sentiment towards a particular stock. Datadog's peer group average for short interest as a percentage of float is 3.27%, which means the company has more short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:15 pm

DIN

Dine Brands International, an affiliate of Dine Brands Global Inc (NYSE:DIN), has entered into an expansion agreement with virtual restaurant platform Franklin Junction. The partnership aims to boost the international expansion of IHOP and Applebee's through Franklin Junction's Host Kitchen platform. The initial expansion will target markets in Japan, the Netherlands, France, and Belgium, with the first launch in Japan by Q4 of 2023.

Portfolio Pulse from Shivani Kumaresan

July 18, 2023 | 1:14 pm

PIRS

Shares of Pieris Pharmaceuticals have been halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 1:13 pm

APO

CTRA

JPM

RDNT

UEC

Jim Cramer, host of CNBC's 'Mad Money Lightning Round', expressed his bullish stance on JPMorgan Chase & Co. (JPM), citing its low valuation and strong recent quarter. He also mentioned RadNet, Inc. (RDNT), but suggested it was overpriced compared to GE HealthCare Technologies Inc. (GEHC). Cramer did not recommend Apollo Global Management, Inc. (APO) due to lack of clarity about its operations. He also expressed a preference for natural gas over nuclear power, favoring Coterra Energy Inc. (CTRA) over Uranium Energy Corp. (UEC).

Portfolio Pulse from Lisa Levin

July 18, 2023 | 1:13 pm

KPTI

Karyopharm Therapeutics Inc's shares are trading higher after the FDA granted Fast Track Designation to the development program of selinexor for myelofibrosis. The company initiated a pivotal Phase 3 trial in June 2023 and plans to expand its clinical development program in myelofibrosis. Top-line data from the Phase 3 study is expected in 2025. KPTI shares are up 20.90% at $1.85 during the premarket session.

Portfolio Pulse from Vandana Singh

July 18, 2023 | 1:12 pm

ARDS

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) shares are gaining after the company announced positive feedback from the European Medicines Agency on its proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301. The agreements by the EMA were similar to those agreed by the FDA. The company's shares are up 29.40% at $0.34 during the premarket session.

Portfolio Pulse from Vandana Singh

July 18, 2023 | 1:09 pm